Approximately 100 Discovery positions will be eliminated as a result of these changes." The Big Biotech, which employs 8,000 R&D staffers worldwide, is also renovating labs in New Jersey. Bristol-Myers Squibb's big reorganization fits into the industry's new model for R&D. Large, scattered groups are out as big organizations gravitate toward the big hubs. GlaxoSmithKline ($GSK) and Amgen ($AMGN) have offered two recent examples of that trend, which has benefited hubs like Boston/Cambridge and the Bay Area while inflicting painful cuts in outlying areas. Biopharma companies are also concentrating on core areas, sometime shedding early-stage work--reflected in Merck's ($MRK) recent downsizing at the newly acquired Cubist and the big asset swap that occurred between GlaxoSmithKline and Novartis ($NVS). Bristol-Myers noted that the elimination of discovery work in virology doesn't signal a retreat from its more advanced work in the field.